Nebenwirkungen · Bavencio
Bavencio 20 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 17
HOS-138067 · Präparat HOS-098135
Immune-mediated adrenal insufficiency did not lead to discontinuation of avelumab in any patient. Eight (88.9%) patients with immune-mediated adrenal insufficiency were treated with corticosteroids and 2 (25%) of the 8 patients received high-dose corticosteroids (≥ 40 mg prednisone or equivalent) for a median of 8 days (range: 5 days to 11 days). Adrenal insufficiency resolved in 4 (44.4%) of the 9 patients at the time of data cut-off.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-21T17:00:00Z · SHA-256 f560adf7edd288792b6bab7ddc310f7fd91bf0a1dac83f52d792a783eade17a3 · Passage 21225727707abb6180e04156ebb3cab4bb509a2c6da884f0990a61a07fcc20b1 · Zeichen 20513–20952 im Abschnitt